NANJING, China, Sept. 12 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the promotions of Mr. Jindong Zhou and Mr. Xiaojin Yin to Executive Vice President and Senior Vice President, respectively, and the appointment of Mr. Qingsen Li to the newly created position of Vice President of Human Resources.
Mr. Jindong Zhou joined Simcere in 1994 and has over twenty years of experience in the pharmaceutical industry. Prior to his promotion, he served as Vice President of Manufacturing overseeing several GMP manufacturing plants. As Executive Vice President, he broadens his responsibilities beyond manufacturing to include sales and marketing and other executive office support.
Mr. Xiaojin Yin joined Simcere in 2000, and as Vice President of R&D he introduced both Bicun and Endu to the Company together with many other pipeline products. In his new role as Senior Vice President of R&D, he will continue to oversee the Company's R&D activities with a focus on bringing more pipeline products and senior R&D professionals to the Company.
Mr. Qingsen Li joins Simcere from Taikang Insurance Co. Ltd. where he was General Manager of Training and Human Resources. Prior to Taikang, Mr. Li held the position of Vice President and Director of Human Resources at Novartis China.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere, commented: "We are delighted to promote Jindong Zhou and Xiaojin Yin to new positions with increased management responsibilities. These executives have made many valuable contributions to Simcere and we know their strong leadership and execution capabilities will continue to help Simcere achieve further growth."
Mr. Ren added: "We are also pleased to welcome Qingsen Li to our management team. His vast experience with both local Chinese and multinational companies will bring human resources at Simcere to a new level and reinforces our commitment in bringing onboard the best quality talent into the Company."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
|SOURCE Simcere Pharmaceutical Group|
Copyright©2008 PR Newswire.
All rights reserved